Catalyst Wire Dossier Catalyst Wire Dossier

rhTPO (recombinant human thrombopoietin)

recombinant human thrombopoietin
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for rhTPO (recombinant human thrombopoietin), covering 2019-09-13 to 2026-01-12. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients. [Phase 2]

See pricing